Abstract | AIMS: METHODS: RESULTS: Lower levels of VCAM-1 (P = .015, OR = 3.11, 95% CI 1.27-8.08) and VEGF-A (P = .007, OR = 3.47, 95% CI 1.40-8.75) were associated with a higher risk of hypertension. Levels of angiopoietin-2 were not associated with hypertension. The multivariable model indicates an independent effect of VCAM-1 (P = .018, OR = 3.18, 95% CI 1.25-8.68) and VEGF-A (P = .008, OR = 3.77, 95% CI 1.44-10.21). The presence of low levels of both VCAM-1 and VEGF-A had an OR of 9.46 (95% CI 3.08-33.26, P = 1.70 × 10-4 ) for the risk of hypertension (sensitivity of 41.4%, specificity of 93.1%, PPV of 70.6% and NPV of 79.8%). CONCLUSIONS:
|
Authors | Julia C F Quintanilha, Kelli Hammond, Yingmiao Liu, Federica Marmorino, Beatrice Borelli, Chiara Cremolini, Andrew B Nixon, Federico Innocenti |
Journal | British journal of clinical pharmacology
(Br J Clin Pharmacol)
Vol. 88
Issue 9
Pg. 4171-4179
(09 2022)
ISSN: 1365-2125 [Electronic] England |
PMID | 35437784
(Publication Type: Journal Article)
|
Copyright | © 2022 British Pharmacological Society. |
Chemical References |
- Angiogenesis Inhibitors
- Angiopoietin-2
- VEGFA protein, human
- Vascular Cell Adhesion Molecule-1
- Vascular Endothelial Growth Factor A
|
Topics |
- Angiogenesis Inhibitors
(adverse effects)
- Angiopoietin-2
(blood)
- Humans
- Hypertension
(chemically induced, epidemiology)
- Vascular Cell Adhesion Molecule-1
(blood)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, blood)
|